Cancer Biomarkers

Cancer Biomarkers


Global Cancer Biomarkers Market to Reach US$68.9 Billion by 2030

The global market for Cancer Biomarkers estimated at US$23.2 Billion in the year 2023, is expected to reach US$68.9 Billion by 2030, growing at a CAGR of 16.8% over the analysis period 2023-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis period. Growth in the Genetic Biomarkers segment is estimated at 16.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 21.8% CAGR

The Cancer Biomarkers market in the U.S. is estimated at US$5.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$18.3 Billion by the year 2030 trailing a CAGR of 21.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.4% and 14.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR.

Global Cancer Biomarkers Market – Key Trends & Drivers Summarized

Why Are Cancer Biomarkers Gaining Importance in Modern Oncology?

Cancer biomarkers have become a cornerstone in modern oncology, transforming the way cancer is diagnosed, monitored, and treated. Biomarkers, which are molecules found in blood, tissue, or other body fluids, provide critical information about cancer`s presence, progression, and response to treatment. They allow for earlier and more accurate detection of cancer, often before symptoms manifest, giving patients a better chance at successful treatment. The role of biomarkers extends beyond diagnostics; they are integral to personalized medicine, helping oncologists tailor treatment plans based on an individual`s unique cancer profile. By identifying specific genetic mutations, proteins, or other molecular changes, cancer biomarkers can guide the selection of targeted therapies that improve outcomes and minimize side effects.

The increasing reliance on cancer biomarkers is fueled by the global push toward precision medicine. Biomarkers are used in identifying cancer subtypes and assessing the likelihood of metastasis or recurrence. Their use is rapidly expanding, from well-known cancers like breast, lung, and colorectal cancer, to more complex and rare types. As research continues to uncover new biomarkers, the oncology community is gaining powerful tools to improve patient prognosis, reduce unnecessary treatments, and make informed clinical decisions. As a result, the demand for biomarker-based tests and therapies is accelerating, shaping the future of cancer care.

How Are Technological Advancements Driving the Cancer Biomarkers Market?

Technological advancements in genomics, proteomics, and bioinformatics are revolutionizing the cancer biomarker landscape. High-throughput technologies like next-generation sequencing (NGS) and mass spectrometry are enabling the identification of novel biomarkers with unprecedented precision and speed. These innovations allow researchers to analyze vast amounts of genetic and proteomic data, uncovering complex molecular signatures associated with different cancer types. This capability is crucial in understanding the heterogeneity of cancer and in developing more effective targeted therapies. Liquid biopsies, which detect cancer biomarkers from a simple blood sample, are another major technological advancement that is transforming early detection and monitoring of cancer.

Artificial intelligence (AI) and machine learning are also becoming integral to biomarker discovery and analysis. AI algorithms can process and interpret large datasets from genomic studies, identifying patterns that may be difficult for humans to detect. These technologies are speeding up the identification of actionable biomarkers and aiding in the development of predictive models for cancer outcomes. Additionally, advancements in bioinformatics tools are enabling better integration and analysis of multi-omics data, leading to more comprehensive insights into the molecular mechanisms of cancer. These technological developments are making cancer biomarker testing more accessible, cost-effective, and reliable, further driving market growth.

How Is Consumer Awareness and Demand for Personalized Medicine Shaping the Market?

The growing consumer awareness of personalized medicine is a significant factor propelling the cancer biomarkers market. Patients are increasingly informed about the benefits of targeted therapies and personalized treatment approaches, which rely heavily on biomarkers to identify the most effective treatments for their specific cancer types. As more individuals seek tailored cancer care, healthcare providers are increasingly incorporating biomarker testing into their diagnostic and treatment protocols. This shift towards personalized medicine is not only improving patient outcomes but also enhancing the efficiency of cancer treatment by reducing trial-and-error approaches and minimizing exposure to ineffective therapies.

Pharmaceutical companies are also capitalizing on this trend by developing targeted cancer therapies that are designed to interact with specific biomarkers. The rise of immunotherapies and other targeted treatments, such as checkpoint inhibitors and monoclonal antibodies, is closely tied to the identification and utilization of biomarkers. As patients demand treatments that offer better efficacy and fewer side effects, the integration of biomarkers in drug development is becoming essential. Additionally, the increasing use of direct-to-consumer genetic testing is raising awareness of cancer risk factors, prompting more patients to seek out biomarker-driven diagnostic tests and personalized treatment options.

Growth in the Cancer Biomarkers Market Is Driven by Several Factors

The growth in the cancer biomarkers market is driven by several factors, including advancements in technology, the increasing adoption of personalized medicine, and the rising incidence of cancer globally. Technological innovations, such as next-generation sequencing and liquid biopsy, are enabling the rapid discovery and validation of new biomarkers, making cancer detection and monitoring more precise and less invasive. The demand for non-invasive tests like liquid biopsies is particularly high, as they offer a less painful and more convenient alternative to traditional tissue biopsies, while still providing critical information about tumor dynamics and treatment response.

Another key driver is the rising demand for personalized cancer treatments. As healthcare providers and patients alike seek more effective and tailored treatment options, biomarker-driven therapies are becoming a central part of cancer care. The increasing development of targeted therapies, such as immunotherapies, which rely on specific biomarkers to identify eligible patients, is fueling the demand for biomarker testing. Furthermore, the expanding use of biomarkers in clinical trials is helping pharmaceutical companies accelerate the development of novel cancer therapies, contributing to market growth. Additionally, government initiatives aimed at promoting cancer research, biomarker discovery, and early detection programs are further boosting the adoption of biomarker-based diagnostics and treatments, ensuring sustained growth in the cancer biomarkers market.

Select Competitors (Total 33 Featured) -
  • Abbott Laboratories
  • Agilent Technologiesent
  • Becton, Dickinson and Company
  • Biomérieux Sant
  • Bio-Rad Laboratories
  • Danaher Corporation
  • GE Healthcare
  • Hologic
  • Illuminat
  • Merck & Co.
  • Myriad Genetics
  • Qiagen N.V.
  • Quest Diagnostics
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific


Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Cancer Biomarkers – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Advancements in Genomic Sequencing Technologies Drive Innovations in Cancer Biomarker Discovery
Increasing Use of Biomarkers in Personalized Medicine Propels Targeted Therapy Development
Rising Prevalence of Cancer Worldwide Enhances the Demand for Early Detection Biomarkers
Growth in Liquid Biopsy Adoption Accelerates Market Opportunities for Non-Invasive Cancer Biomarkers
Expansion of Companion Diagnostics Strengthens the Integration of Biomarkers in Clinical Pathways
Role of Artificial Intelligence in Enhancing the Specificity and Sensitivity of Biomarker Detection
Evolving Patent Landscape and Intellectual Property Rights Impacting Cancer Biomarker Development
Advances in Bioinformatics and Data Analytics Propel the Utilization of Biomarkers in Cancer Prognosis
Increased Public and Private Funding for Cancer Research Spurs Biomarker Innovation
Growing Awareness and Adoption of Screening Programs Enrich the Market for Diagnostic Biomarkers
Technological Innovations in Imaging Biomarkers Improve Accuracy in Cancer Diagnostics
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Cancer Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 8: World Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Protein Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Protein Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Protein Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Genetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Genetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Genetic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: World 16-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Omics Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 42: World Historic Review for Omics Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: World 16-Year Perspective for Omics Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Imaging Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 45: World Historic Review for Imaging Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: World 16-Year Perspective for Imaging Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 47: World Recent Past, Current & Future Analysis for Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 48: World Historic Review for Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: World 16-Year Perspective for Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 50: World Recent Past, Current & Future Analysis for Other Profiling Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 51: World Historic Review for Other Profiling Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: World 16-Year Perspective for Other Profiling Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 53: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: USA Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: USA 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 56: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: USA Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: USA 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 59: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: USA Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: USA 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 62: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: USA Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: USA 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
CANADA
TABLE 65: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Canada Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Canada 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 68: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Canada Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Canada 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 71: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Canada Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Canada 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 74: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Canada Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Canada 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
JAPAN
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 77: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Japan Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Japan 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 80: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Japan Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Japan 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 83: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Japan Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Japan 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 86: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Japan Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Japan 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
CHINA
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 89: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: China Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: China 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 92: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: China Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: China 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 95: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: China Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: China 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 98: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: China Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: China 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
EUROPE
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 101: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Europe Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Europe 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 104: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Europe Historic Review for Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Europe 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 107: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Europe Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Europe 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 110: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Europe Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Europe 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 113: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Europe Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Europe 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
FRANCE
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 116: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: France Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: France 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 119: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: France Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: France 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 122: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: France Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: France 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 125: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: France Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: France 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
GERMANY
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 128: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Germany Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Germany 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 131: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Germany Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Germany 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 134: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Germany Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Germany 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 137: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Germany Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Germany 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
ITALY
TABLE 140: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Italy Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Italy 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 143: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Italy Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Italy 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 146: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Italy Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Italy 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 149: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Italy Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Italy 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
UNITED KINGDOM
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 152: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: UK Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: UK 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 155: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: UK Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: UK 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 158: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: UK Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: UK 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 161: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: UK Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: UK 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
SPAIN
TABLE 164: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Spain Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Spain 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 167: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Spain Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Spain 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 170: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Spain Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Spain 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 173: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Spain Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Spain 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
RUSSIA
TABLE 176: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Russia Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Russia 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 179: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Russia Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Russia 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 182: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Russia Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Russia 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 185: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Russia Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Russia 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Rest of Europe Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Rest of Europe Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Europe Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Rest of Europe Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Asia-Pacific Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 204: Asia-Pacific Historic Review for Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Asia-Pacific Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Asia-Pacific Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Asia-Pacific Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
AUSTRALIA
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 215: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Australia Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Australia 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 218: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 219: Australia Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 220: Australia 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 221: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 222: Australia Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 223: Australia 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 224: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 225: Australia Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 226: Australia 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
INDIA
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 227: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 228: India Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 229: India 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 230: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 231: India Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 232: India 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 233: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 234: India Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 235: India 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 236: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 237: India Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 238: India 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 239: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 240: South Korea Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 241: South Korea 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 242: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 243: South Korea Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 244: South Korea 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 245: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 246: South Korea Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 247: South Korea 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 248: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 249: South Korea Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 250: South Korea 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 252: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 255: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 258: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 261: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
LATIN AMERICA
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 263: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 264: Latin America Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 265: Latin America 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 266: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 267: Latin America Historic Review for Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 268: Latin America 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 269: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 270: Latin America Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 271: Latin America 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 272: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 273: Latin America Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 274: Latin America 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 275: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 276: Latin America Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 277: Latin America 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 278: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 279: Argentina Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 280: Argentina 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 281: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 282: Argentina Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 283: Argentina 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 284: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 285: Argentina Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 286: Argentina 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 287: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 288: Argentina Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 289: Argentina 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
BRAZIL
TABLE 290: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 291: Brazil Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 292: Brazil 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 293: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 294: Brazil Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 295: Brazil 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 296: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 297: Brazil Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 298: Brazil 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 299: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 300: Brazil Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 301: Brazil 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
MEXICO
TABLE 302: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 303: Mexico Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 304: Mexico 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 305: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 306: Mexico Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 307: Mexico 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 308: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 309: Mexico Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 310: Mexico 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 311: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 312: Mexico Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 313: Mexico 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 315: Rest of Latin America Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 316: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 318: Rest of Latin America Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 319: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 321: Rest of Latin America Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 322: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 324: Rest of Latin America Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 325: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
MIDDLE EAST
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 326: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 327: Middle East Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 328: Middle East 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 329: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 330: Middle East Historic Review for Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 331: Middle East 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 332: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 333: Middle East Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 334: Middle East 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 335: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 336: Middle East Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 337: Middle East 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 338: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 339: Middle East Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 340: Middle East 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
IRAN
TABLE 341: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 342: Iran Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 343: Iran 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 344: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 345: Iran Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 346: Iran 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 347: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 348: Iran Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 349: Iran 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 350: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 351: Iran Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 352: Iran 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
ISRAEL
TABLE 353: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 354: Israel Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 355: Israel 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 356: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 357: Israel Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 358: Israel 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 359: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 360: Israel Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 361: Israel 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 362: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 363: Israel Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 364: Israel 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 366: Saudi Arabia Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 367: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 369: Saudi Arabia Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 370: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 372: Saudi Arabia Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 373: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 375: Saudi Arabia Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 376: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 377: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 378: UAE Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 379: UAE 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 380: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 381: UAE Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 382: UAE 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 383: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 384: UAE Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 385: UAE 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 386: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 387: UAE Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 388: UAE 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 390: Rest of Middle East Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 391: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 393: Rest of Middle East Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 394: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 396: Rest of Middle East Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 397: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 399: Rest of Middle East Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 400: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
AFRICA
Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 401: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 402: Africa Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 403: Africa 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
TABLE 404: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 405: Africa Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 406: Africa 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
TABLE 407: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 408: Africa Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 409: Africa 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
TABLE 410: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 411: Africa Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 412: Africa 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings